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Abstract
Background: Gastrointestinal stromal tumor (GIST) is a rare gastrointestinal tumor but the most common mesenchymal tumor. It originates 
in the interstitial cells of Cajal, which on their own membranes have a specific antigen designated as CD117 or KIT receptor, a reliable 
indicator of tumor detection and therapy. Case: We reported a case of a 63-year-old male patient, who presented with symptoms of severe 
abdominal pain, discomfort, and secondary anemia. After a physical examination and a CT scan of the abdomen with angiography, the 
presence of a large tumor in the right hypochondrium was detected. Blood tests showed a high C-reactive protein and low hemoglobin. 
The patient had an exploratory laparotomy on his abdomen with complete removal of the tumor growth, which was then histologically 
analyzed. The obtained result from the histological analysis showed a high-degree of GIST. Conclusion: Early diagnosis of GISTs is of para-
mount importance to reduce mortality rate. This requires good background in pathobiology and knowledge of the physical manifestations 
of this malignant tumor. When this is combined with various imaging techniques, it becomes the gold standard method for GIST diagnosis. 
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Introduction
Gastrointestinal stromal tumor (GIST) represents only 1-3% of 
all gastrointestinal tumors but is the most common mesenchy-
mal tumor, with a prevalence of 80%.1 This tumor originates in 
the interstitial cells of Cajal (ICC). These interstitial cells are 
innervated by the peripheral nerves and placed in the plexus 
mesentericus, thus functioning as pacemakers to determine 
the motility rhythm of the digestive tract.2-4 GIST is asympto-
matic in 35% of clinical cases, while in other cases it manifests 
as abdominal pain, discomfort (heavy sensation as if having a 
foreign body in the abdomen), bleeding, and secondary ane-
mia.5 As for its localization, it may be located in the digestive 
tract or outside it, as an extra GIST in the abdominal pelvic 
cavity, omentum, mesenterium, uterus, or retroperitoneally.2,6 
It is localized in the stomach in 60–70% of the cases, followed 
by small intestine in 20–25% of cases, colorectal in 5% of cases, 
and esophageal in 5% of cases.7
The incidence of GIST has increased over time from 0.028 per 
100,000 in 1992 to 0.688 per 100,000 in 2002, and affects 7–14 
people in a million at present.7 Statistics show that there is no 
significant difference between sexes, and the male-to-female 
ratio is 1:1.7 The usual age when GIST is diagnosed is between 
55 and 60 years.
GIST is a challenge for modern medicine and research since it 
has a late manifestation due to the long latency period. It is 
also of great concern for medical fellows since it is increasingly 
present in gastrointestinal pathology with rather high rate of 
mortality. It is therefore important to ensure a timely diagnosis, 
followed by chemotherapy and/or minimally-invasive surgical 
treatment.
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Key Points:
• GIST manifests as abdominal pain, discomfort (heavy sensation as if 
from a foreign body in the abdomen), bleeding and secondary anemia.
• Clinical diagnostics of GIST mainly consists of imaging procedures and 
histological analysis with immuno-histochemical staining.
• Early diagnosis by itself means low risk for affected patients and 
promises good outcomes in terms of relapse and survival for patients 
with GIST.
For a long period of time, GIST was considered a type of leiom-
yoma or neuroma, until immuno-histochemical staining tech-
niques revealed that the tumor is a specific type of mesenchy-
mal tumor. The ICC cells from which it derives are cells that 
have a specific antigen on their own membrane, designated as 
CD117 or KIT tyrosine kinase receptor. This is present in over 
85% of these tumors, which calls for the recommended mono-
clonal anti-KIT therapy (imatinib and sunitinib).2,8,9 Furthermo-
re, in 3–5% of GIST, there is a positive platelet derived growth 
factor subunit A (PDGFA).6 This receptor shows exact same cha-
racteristics as KIT. There is also a third form of GIST expression 
called the wild type, which is immuno-histochemically positive 
on insulin-like growth factor 1 receptor (IGF1R). Microscopica-
lly, the GIST can occur in three forms: spindle cells (the most 
common type: 70%), epitheloid cells (20%) and mixed (10%).10  
Macroscopically, GIST is characterized by multi-nodularity, whe-
re the surface may be either smooth or granular, with zones of 
hemorrhage, necrosis, calcification and cystic changes.10
The Case
A 63-year-old male presented with abdominal pain and discom-
fort in the lower right abdominal quadrant with propagation 
towards the right groin. The symptoms, though less severely, 
appeared eight months before his hospitalization. The pain 
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was treated with analgesics, and echo-tomography of the ab-
domen was made, but no visible pathological changes were 
found. Month by month, his pain and discomfort grew in inten-
sity, yet the patient did not seek any medical attention. Right 
before his hospitalization, the patient suffered another pain 
attack so high in intensity that knocked him unconscious. He 
was immediately hospitalized in the clinic, where a physical 
examination of the abdomen was performed. With a deep pal-
pation in the right hypochondrium, a large-size tumor which 
was insensitive to pain was palpated, whereas the liver and 
spleen were impalpable. Laboratory blood tests showed low 
level of hemoglobin (99 g/L) indicating secondary anemia, and 
the urine analysis showed decreased lactate dehydrogenase 
(LDH) (179 U/L; normal range = 213–423 U/L) and increased C-re-
active protein (CRP) (23.6 mg/L; normal range = 0.0–5.0 mg/L), 
indicating an active inflammation. 
CT angiography of abdomen showed the following results: tu-
mor mass in right hemiabdomen, sub-hepatic, next to the he-
patic flexure medial of ceco-ascendens and extends distally 
almost to the right iliac fossa. The tumor mass was visibly 
re-stained with a stronger contrast. It was attached to a large 
sarcomatoid mass with mixed interiority, without significantly 
increased LGL (Figure 1). Additional medical check-up was con-
ducted, but no other pathological changes were found. The pa-
tient weighed 161 pounds (73 kg), and his blood pressure was 
135/90 mmHg. Based on the results, the diagnosis was Tu. ab-
dominis sang. Haemascos, Anemia sec. A laparotomy explora-
tion was then performed to remove the neoplastic tissue in its 
entirety and to further subject it to histological analysis. Medial 
laparotomy was performed operationally with hemoperitoneum 
findings revealing a bleeding cystic type of neoplasm in the 
right hypochondrium (Figure 2). Extirpation of the neoplasm 
was done in full. The patient’s stomach was deserosated, after 
which it was serosated with more individual stitches. Profuse 
lavage followed, and upon determining exact hemostasis, two 
drains were placed—one subhepatally and one in rectovesical 
excavation. The surgical wound was closed in layers. The entire 
surgical treatment was done with general endotracheal anes-
thesia. The tissue material was sent to the pathology laboratory 
for ultimate histological analysis. Fourteen pieces of paraffin 
were taken for analysis.
The tumor mass was 18 cm × 11 cm × 5 cm in size and weighed 
1.5 pounds (675 g) (Figure 3). A thin connective capsule was 
visible on the surface. At the intersection, the tumor tissue had 
a sponge-like appearance with multi-cystic degeneration and 
bleeding areas.
Microscopic analysis showed neoplastic proliferation embed-
ded with epithelial cells in solid arrangement. Magnification 
of the cells shows eosinophilic and bright cytoplasm with oval 
or elongated nuclei. In some of these nuclei, nucleoli were 
also clearly visible. The cells were pleomorphic with manifested 
nuclei atypia. The tumor also exhibited blood vessels, edema, 
and chronic inflammation. An immuno-histochemical method 
was employed to prove the origin of the tumor by using CD117, 
CD34, actin, Vimetin, C-100, CKWS, Melan A, and HMB 45. Strong 
positivity of CD117 and CD34 was evident, whereas actin was 
positive in only 10%. Proliferative findings of Ki-67 were <10%. 
Mitotic figures were >5/50 HPF, as per usual. This finding sug-
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Figure 1. CT Angiography of Abdomen
Axial or transverse section of abdomen with a large sarcomatoid lesion on the right side (white arrow)
Figure 2. Hemorrhagic Cystic Type of Neoplasm Was Found in the Right Hypochondrium
Figure 3. Macroscopic Finding of Tumor Mass
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gests gastrointestinal stromal tumor, with a high mitotic index, 
pT4. Since a high-risk GIST was established, the patient was 
sent to the Oncology Clinic for further treatment. The oncologi-
cal treatment included chemotherapy with imatinib, a specific 
monoclonal antibody for tyrosine kinase receptor, in a dosage 
of 400 mg twice a day.  The follow-up imaging was to be done 
every six months during the adjuvant therapy, every 3–4 mon-
ths in the first two years after the received chemotherapy, and 
every 6–12 months for up to 10 years after the surgery.
Discussion
Reaching the diagnosis of GIST is mainly based on imaging pro-
cedures and histological analysis with immuno-histochemical 
staining. Imaging procedures such as endoscopy, CT, MRI and 
PET-scan are needed to determine the localization and size of 
tumor size as well as monitor the effectiveness of therapy and 
relapse of illness. Histological analysis is used to determine the 
distinct characteristics and nature of the tumor tissue through 
immuno-histochemical staining and the use of anti-CD117 anti-
bodies to prove the presence of KIT receptor.5,7
The classification of GIST is based on the Risk Stratification Sys-
tem of primary GIST, which determines the risk of recurrence 
and metastasis and indirectly informs the planning of therapy 
and patient survival.6 The prognostic models used in this sys-
tem include variables such as size, localization, and mitotic 
index cutoff of 5/50 HPF to stratify patients into very low, low, 
medium and high risk groups (very low risk: 0%, low: 3–9%, 
medium: 12–24%, high: 55–90% with a possibility of recurrence 
and metastasis and inversely proportional to that, of survival).7
The GISTs are also characterized by metastasis that commonly 
occurs in the abdominal cavity and liver; they can be found 
infrequently in the soft tissues and bones as well.6,10 But typical 
of GIST is that it does not metastasize to the lymph nodes, i.e. 
its pattern of metastasis is exclusively hematogenous. A series 
of studies show that the median survival in patients with GIST 
is 60 months when no metastases are found. In cases when the 
tumor metastasizes, the chance of survival is 12–19 months.1
Conclusion
Early diagnosis of GIST is of crucial importance to reduce morta-
lity rate among affected patients. This requires good knowledge 
of pathobiology and the characteristics of this tumor, especially 
of the KIT receptor that is GIST-specific. Immuno-histochemical 
staining has high specificity and sensitivity and contributes to 
a reliable diagnosis of the GIST. This technique combined with 
different imaging methods such as CT, MRI, ECHO, and PET SCAN 
is the gold standard for tumor diagnosis.
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